Burkitt Lymphoma

P1, N=16, Completed, Acepodia Biotech, Inc. | Active, not recruiting --> Completed | N=42 --> 16 | Trial completion date: Sep 2027 --> Mar 2026 | Trial primary completion date: Jul 2026 --> Mar 2026

Importantly, therapeutic strategies aimed at interrupting viral miRNA function, restoring host tumor-suppressor pathways, and re-sensitizing tumor cells to immune surveillance hold promise. This review synthesizes current mechanistic insights into EBV-encoded miRNAs in oncogenesis, elaborates on their roles in lymphoma pathogenesis, and evaluates the translational potential of miRNA-targeted therapies in EBV-associated malignancies.

P1, N=30, Active, not recruiting, City of Hope Medical Center | Trial completion date: Jun 2026 --> May 2027

P2, N=300, Recruiting, Masonic Cancer Center, University of Minnesota | Trial completion date: Jun 2027 --> Jun 2028 | Trial primary completion date: Jun 2026 --> Jun 2027

P2, N=43, Not yet recruiting, AIDS Malignancy Consortium

P1, N=42, Active, not recruiting, Acepodia Biotech, Inc. | Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2025 --> Jul 2026

Herein, we report a rare occurrence of a double-hit lymphoma with plasmablastic features in a patient with a history of follicular lymphoma (FL) aberrantly expressing keratin in the transformed component posing a diagnostic conundrum. Immunohistochemistry and molecular work-up in conjunction with clinical history were essential in arriving at the correct diagnosis and thus illustrating a diagnostic pitfall.

In this contemporary POL series, clinicopathologic heterogeneity was prominent, and laboratory profiles frequently overlapped with ovarian malignancy work-up. Outcomes may be favorable among patients receiving timely, subtype-appropriate systemic treatment.

Following a protocol amendment to evaluate the efficacy of siltuximab as a first-line treatment of CRS, one patient received siltuximab with full resolution of CRS after two doses without needing additional anti-cytokine-directed therapies...This extended experience demonstrates that CD19.22.BBζ CAR T-cell therapy is safe and clinically active, particularly as a bridge to HSCT. Non-response was confined to patients with non-CNS EMD, highlighting the persistent challenge of effectively targeting EMD and informing the design of future CAR constructs.Trial registration numberNCT03448393.

This case establishes the shared clonal origin between AITL and BL arising in the setting of CH and provides additional biological insight into the development of B-cell lymphoma associated with AITL.

P1, N=34, Active, not recruiting, National Cancer Institute (NCI) | N=55 --> 34 | Recruiting --> Active, not recruiting

While functional assays were not performed in this study, previous reports indicate that immature neutrophils can exhibit tumor-promoting functions. Therefore, the observed shift in neutrophil profiles may reflect phenotypic changes associated with malaria exposure that could contribute to a permissive environment for BL.